The association between gastro-oesophageal reflux and exacerbations of bronchiectasis: data from the EMBARC registry

McDonnell, Melissa; Rutherford, Robert; Soyza, Anthony De; Loebinger, Michael R.; Goeminne, Pieter; Haworth, Charles; Blasi, Francesco; Vendrell, Montserrat; Ringshausen, Felix C.; Aliberti, Stefano; Polverino, Eva; Chalmers, James

doi:10.1183/1393003.congress-2017.oa1968

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the clinical efficacy of current treatment of GORD has not been demonstrated, clinicians should assess comorbid GORD in patients with bronchiectasis who are hampered by frequent exacerbations. 13 We also suggest that collaborative work between pulmonologists and gastroenterologists may be beneficial for the control of both diseases. Also, clinical studies are urgently needed to test whether controlling GORD can improve the treatment outcomes of bronchiectasis and vice versa.…”

Section: Discussionmentioning

confidence: 88%

“…[9][10][11][12] GORD is associated with more symptoms, such as cough and sputum amount, reduced lung function, disease severity, and radiologic severity, as well as increased risk of exacerbation. 10,12,13 However, few studies have evaluated the association between GORD and healthcare use and medical costs in patients with bronchiectasis. 12 South Korea provides universal health coverage for almost all Korean citizens.…”

Section: Introductionmentioning

confidence: 99%

“… 9 – 12 GORD is associated with more symptoms, such as cough and sputum amount, reduced lung function, disease severity, and radiologic severity, as well as increased risk of exacerbation. 10 , 12 , 13 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gastro-oesophageal reflux disease increases healthcare use and medical costs in patients with bronchiectasis: a Korean nationwide population-based study

Yoon

Kim

Ryu

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Gastro-oesophageal reflux disease (GORD) is not only a common aetiology but also accompanying comorbidity of non-cystic fibrosis bronchiectasis (bronchiectasis). However, the association between GORD and the disease burden of bronchiectasis has not been well evaluated. Our study aimed to evaluate whether GORD is associated with increased healthcare use and medical costs in patients with bronchiectasis. Methods: We analyzed the data from 44,119 patients with bronchiectasis using a large representative Korean population-based claim database between 2009 and 2017. We compared the healthcare use [outpatient department (OPD) visits and emergency room (ER) visits/hospitalizations] and medical costs in patients with bronchiectasis according to the presence or absence of GORD. Results: The prevalence of GORD in patients with bronchiectasis tended to increase during the study period, especially in the 50s and older population. GORD was associated with increased use of all investigated healthcare resources in patients with bronchiectasis. Healthcare use including OPD visits (mean 47.6/person/year versus 30.0/person/year), ER visits/hospitalizations (mean 1.7/person/year versus 1.1/person/year), and medical costs (mean 3564.5 Euro/person/year versus 2198.7 Euro/person/year) were significantly higher in bronchiectasis patients with GORD than in those without GORD ( p < 0.001 for all). In multivariable analysis, bronchiectasis patients with GORD showed 1.44-fold (95% confidence interval = 1.37–1.50) and 1.26-fold (95% confidence interval = 1.19–1.33) increased all-cause and respiratory-related ER visits/hospitalizations relative to those without GORD, respectively. After adjusting for potential confounders, the estimated total medical costs (mean 4337.3 versus 3397.4 Euro/person/year) and respiratory disease-related medical costs (mean 920.7 versus 720.2 Euro/person/year) were significantly higher in bronchiectasis patients with GORD than in those without GORD ( p < 0.001 for both). Conclusion: In patients with bronchiectasis, GORD was associated with increased healthcare use and medical costs. Strategies to reduce the disease burden associated with GORD are needed in patients with bronchiectasis.

show abstract

Section: Discussionmentioning

confidence: 88%